A comprehensive review of oral hypoglycaemic drugs and their oral health correlates

Nishtha Bhardwaj; Shivani Mehta

doi:10.18203/2320-6012.ijrms20252160

Authors

Nishtha Bhardwaj Department of Pharmacovigilance, Continuum India LLP, Chandigarh, India
Shivani Mehta Department of Pharmacovigilance, Continuum India LLP, Chandigarh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20252160

Keywords:

Oral hypoglycemic drugs, Diabetes mellitus, Oral health

Abstract

Oral hypoglycaemic drugs (OHDs) are vital in the effective management of type 2 diabetes mellitus (T2DM), a widespread metabolic disorder that affects millions globally. While these medications excel at controlling blood glucose levels, they can also lead to significant oral health challenges. This article delves into the various pharmacological classes of OHDs and highlights their potential impacts on oral health, including issues such as dry mouth (xerostomia), periodontal disease, taste changes, delayed healing, and a higher susceptibility to oral infections. It is imperative for healthcare providers, especially dental professionals, to understand these connections, as recognizing the oral health implications of diabetes is essential for delivering comprehensive and effective care to diabetic patients. Proper awareness and proactive management can make a substantial difference in the overall well-being of those living with diabetes.

Metrics

Metrics Loading ...

References

International Diabetes Federation (IDF). IDF Diabetes Atlas, 10th ed. Brussels: International Diabetes Federation. 2021.

American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes. 2021;44(1):111-24. DOI: https://doi.org/10.2337/dc21-S009

Preshaw PM, Alba AL, Herrera D, Jepsen S, Konstantinidis A, Makrilakis K, et al. Periodontitis and diabetes: a two-way relationship. Diabetologia. 2012;55(1):21-31. DOI: https://doi.org/10.1007/s00125-011-2342-y

Ship JA, Chavez EM, Doerr PA, Henson BS, Sarmadi M. Diabetes and oral health: an overview. J Contemp Dent Pract. 2003;4(4):1-14. DOI: https://doi.org/10.14219/jada.archive.2003.0367

López-Pintor RM, Casañas E, González-Serrano J, Serrano J, Ramírez L, de Arriba L. Xerostomia, hyposalivation, and salivary flow in patients with type 2 diabetes treated with oral antidiabetic agents. J Diabetes Res. 2016;2016:4372852. DOI: https://doi.org/10.1155/2016/4372852

Taylor GW, Borgnakke WS. Periodontal disease: associations with diabetes, glycemic control and complications. Oral Diseases. 2008;14(3):191-203. DOI: https://doi.org/10.1111/j.1601-0825.2008.01442.x

Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. Periodontol 2000. 2007;44(1):127-53. DOI: https://doi.org/10.1111/j.1600-0757.2006.00193.x

Madhuri G. Evaluation of the Efficacy of 1% Metformin Gel in the Treatment of Intrabony Defects in Chronic Periodontitis Using Minimally Invasive Surgical Technique: A Randomized Controlled Clinical Trial (Master's thesis, Rajiv Gandhi University of Health Sciences (India)). 2019.

Mushtaq I, Shukla P, Malhotra G, Dahiya V, Kataria P, Joshi CS. Comparative evaluation of 1% metformin gel as an adjunct to scaling and root planning in the treatment of chronic periodontitis with scaling and root planing alone: A randomized controlled clinical trial. Int J Oral Care Res. 2018;6(2):79-88.

Pradeep AR, Rao NS, Naik SB, Kumari M. Locally delivered 1% metformin gel in the treatment of smokers with chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2013;84:1165-71. DOI: https://doi.org/10.1902/jop.2012.120298

Garrido IS, Ramírez L, Corcuera MM, Garrido E, Sánchez L, Acitores MLM, et al. Xerostomia and Salivary Dysfunction in Patients With

Diabetes Mellitus. A Cross-Sectional Study. J Oral Pathol Med. 2024;53:622-36. DOI: https://doi.org/10.1111/jop.13583

Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care. 2007;30(6):1335-43. DOI: https://doi.org/10.2337/dc07-0228

Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diabetes Metab Syndr Obes. 2020;13:161-74. DOI: https://doi.org/10.2147/DMSO.S233538

Soysa NS, Samaranayake LP, Ellepola AN. Diabetes mellitus as a contributory factor in oral candidiasis. Diabetic Med. 2006;23(5):455-9. DOI: https://doi.org/10.1111/j.1464-5491.2005.01701.x

Forssell H, Jaaskelainen S, Tenovuo O, Hinkka S. Sensory dysfunction in burning mouth syndrome. Pain. 2002;99(1-2):41-7. DOI: https://doi.org/10.1016/S0304-3959(02)00052-0

Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. Clin Endocrinol Metabol. 2006;91(9):3349-54. DOI: https://doi.org/10.1210/jc.2005-2226

Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabetic Med. 1997;14(1):29-34. DOI: https://doi.org/10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V

Malamed SF. Medical emergencies in the dental office. 7th edit, Publisher, Elsevier India. 2015.

Vernillo, Anthony T. Dental considerations for the treatment of patients with diabetes mellitus. J Am Dental Associat. 2003;134:24-33. DOI: https://doi.org/10.14219/jada.archive.2003.0366

Femiano F, Lanza A, Buonaiuto C, Gombos F, Rullo R, Festa V, et al. Oral manifestations of adverse drug reactions: guidelines. J Eur Acad Dermatol Venereol. 2008;22(6):681-91. DOI: https://doi.org/10.1111/j.1468-3083.2008.02637.x